福安药业(300194) - 2024 Q2 - 季度业绩预告

Financial Performance - The company expects a net profit attributable to shareholders of approximately 205 million to 225 million yuan, representing a year-on-year growth of 27.42% to 39.85%[8] - The estimated net profit for the reporting period is 160.89 million yuan, with a net profit of 142.96 million yuan after deducting non-recurring gains and losses[3] - Non-recurring gains and losses are expected to impact net profit by around 15 million yuan, primarily from government subsidies received[5] Revenue Growth - The increase in sales volume of certain products has significantly contributed to revenue growth[8] - The proportion of products won in national centralized procurement has increased, leading to a decrease in the ratio of selling expenses to operating income[8]